U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ATRA?
Source: Benzinga
- Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
- Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
- FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
- Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.590
Low
18.00
Averages
21.50
High
25.00
Current: 9.590
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws.
- Regulatory Scrutiny: Atara's Biologics License Application for tabelecleucel faced a Complete Response Letter from the FDA due to manufacturing issues, resulting in a 40.5% stock price drop on January 16, 2025, highlighting significant regulatory risks.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's active IND applications due to unresolved GMP compliance issues identified during inspections, raising further concerns about the company's product development capabilities.
- Stock Price Volatility: On January 12, 2026, Atara received another Complete Response Letter from the FDA, causing a 56.99% decline in stock price, indicating a severe loss of investor confidence in the company's future prospects.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the FDA approval prospects for its tabelecleucel Biologics License Application, thereby significantly impacting the company's financial condition.
- Choosing Legal Counsel: The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record, noting that many firms issuing notices lack the capability to handle securities class actions and may merely act as intermediaries, failing to provide effective legal support for investors.
- Investor Losses: As the true details emerged, investors may have suffered damages; the Rosen Law Firm has recovered over $438 million for investors in 2019 alone, showcasing its strength and success in securities class action litigation.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara faces a class action from May 20, 2024, to January 9, 2026, alleging that manufacturing issues and clinical trial risks overstated its FDA approval prospects, potentially leading to significant negative impacts on its financial condition.
- Coty's Underperformance: Coty Inc. is involved in a class action from November 5, 2025, to February 4, 2026, claiming that its Consumer Beauty segment underperformed and increased marketing investments compressed margins, rendering the company's positive statements materially misleading.
- Super Micro Computer Compliance Issues: Super Micro Computer faces a class action from February 2, 2024, to March 19, 2026, due to server sales to Chinese companies violating U.S. export control laws, indicating material weaknesses in compliance controls that jeopardize business prospects.
- ImmunityBio's Overstated Capabilities: ImmunityBio is part of a class action from January 19, 2026, to March 24, 2026, alleging that executive claims about Anktiva's capabilities were materially misleading, which could undermine investor confidence in the company's operations.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, aiming to recover damages for investors who purchased securities between May 20, 2024, and January 9, 2026, indicating a severe blow to investor confidence in the company's future prospects.
- Allegations of False Statements: The complaint alleges that Atara's executives failed to disclose significant manufacturing issues within the ALLELE study that could jeopardize FDA approval for tabelecleucel, exposing investors to substantial financial losses.
- Increased Regulatory Risks: The identified manufacturing deficiencies have heightened Atara's risk of regulatory scrutiny, which not only jeopardizes ongoing clinical trials but also poses a significant threat to the company's overall financial health, exacerbating market uncertainty.
- Investor Rights Protection: Bronstein, Gewirtz & Grossman, LLC offers risk-free legal representation, committing to charge fees only upon successful recovery, aiming to provide legal support for affected investors and ensure their rights are upheld.
See More
Faruqi & Faruqi Investigates Atara Investor Claims
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc., particularly for investors who purchased or acquired securities between May 20, 2024, and January 9, 2026, highlighting the firm's commitment to investor rights.
- Legal Consultation Opportunity: Investors can directly contact Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights, indicating the firm's proactive support for affected investors.
- Class Action Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action against Atara, emphasizing the importance of timely action.
- Potential Market Impact: This investigation may negatively affect Atara's stock price, reflecting market concerns over the company's future legal risks, prompting investors to monitor developments closely to safeguard their interests.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of securities laws, involving trades from May 20, 2024, to January 9, 2026, with a deadline of May 22, 2026, for investors to join the case.
- False Statements Allegation: The complaint alleges that Atara made false and misleading statements regarding its ALLELE study, which suffered from manufacturing issues, making FDA approval for its tabelecleucel biologics license application unlikely, thus misleading investors throughout the class period.
- Increased Regulatory Risk: Atara's manufacturing deficiencies have heightened its regulatory risk, which not only impacts its market reputation but also poses potential future legal liabilities and financial losses, leading to significant risks for investors.
- Investor Losses: As the market became aware of the truth regarding Atara, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to participate in the lawsuit to seek compensation, highlighting serious deficiencies in the company's transparency and compliance.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws.
- Regulatory Scrutiny: Atara's Biologics License Application for tabelecleucel faced a Complete Response Letter from the FDA due to manufacturing issues, resulting in a 40.5% stock price drop on January 16, 2025, highlighting significant regulatory risks.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's active IND applications due to unresolved GMP compliance issues identified during inspections, raising further concerns about the company's product development capabilities.
- Stock Price Volatility: On January 12, 2026, Atara received another Complete Response Letter from the FDA, causing a 56.99% decline in stock price, indicating a severe loss of investor confidence in the company's future prospects.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the FDA approval prospects for its tabelecleucel Biologics License Application, thereby significantly impacting the company's financial condition.
- Choosing Legal Counsel: The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record, noting that many firms issuing notices lack the capability to handle securities class actions and may merely act as intermediaries, failing to provide effective legal support for investors.
- Investor Losses: As the true details emerged, investors may have suffered damages; the Rosen Law Firm has recovered over $438 million for investors in 2019 alone, showcasing its strength and success in securities class action litigation.
See More
Multiple Companies Face Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara faces a class action from May 20, 2024, to January 9, 2026, alleging that manufacturing issues and clinical trial risks overstated its FDA approval prospects, potentially leading to significant negative impacts on its financial condition.
- Coty's Underperformance: Coty Inc. is involved in a class action from November 5, 2025, to February 4, 2026, claiming that its Consumer Beauty segment underperformed and increased marketing investments compressed margins, rendering the company's positive statements materially misleading.
- Super Micro Computer Compliance Issues: Super Micro Computer faces a class action from February 2, 2024, to March 19, 2026, due to server sales to Chinese companies violating U.S. export control laws, indicating material weaknesses in compliance controls that jeopardize business prospects.
- ImmunityBio's Overstated Capabilities: ImmunityBio is part of a class action from January 19, 2026, to March 24, 2026, alleging that executive claims about Anktiva's capabilities were materially misleading, which could undermine investor confidence in the company's operations.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, aiming to recover damages for investors who purchased securities between May 20, 2024, and January 9, 2026, indicating a severe blow to investor confidence in the company's future prospects.
- Allegations of False Statements: The complaint alleges that Atara's executives failed to disclose significant manufacturing issues within the ALLELE study that could jeopardize FDA approval for tabelecleucel, exposing investors to substantial financial losses.
- Increased Regulatory Risks: The identified manufacturing deficiencies have heightened Atara's risk of regulatory scrutiny, which not only jeopardizes ongoing clinical trials but also poses a significant threat to the company's overall financial health, exacerbating market uncertainty.
- Investor Rights Protection: Bronstein, Gewirtz & Grossman, LLC offers risk-free legal representation, committing to charge fees only upon successful recovery, aiming to provide legal support for affected investors and ensure their rights are upheld.
See More
Faruqi & Faruqi Investigates Atara Investor Claims
- Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc., particularly for investors who purchased or acquired securities between May 20, 2024, and January 9, 2026, highlighting the firm's commitment to investor rights.
- Legal Consultation Opportunity: Investors can directly contact Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights, indicating the firm's proactive support for affected investors.
- Class Action Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action against Atara, emphasizing the importance of timely action.
- Potential Market Impact: This investigation may negatively affect Atara's stock price, reflecting market concerns over the company's future legal risks, prompting investors to monitor developments closely to safeguard their interests.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of securities laws, involving trades from May 20, 2024, to January 9, 2026, with a deadline of May 22, 2026, for investors to join the case.
- False Statements Allegation: The complaint alleges that Atara made false and misleading statements regarding its ALLELE study, which suffered from manufacturing issues, making FDA approval for its tabelecleucel biologics license application unlikely, thus misleading investors throughout the class period.
- Increased Regulatory Risk: Atara's manufacturing deficiencies have heightened its regulatory risk, which not only impacts its market reputation but also poses potential future legal liabilities and financial losses, leading to significant risks for investors.
- Investor Losses: As the market became aware of the truth regarding Atara, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to participate in the lawsuit to seek compensation, highlighting serious deficiencies in the company's transparency and compliance.
See More
